Will active surveillance for clinically localized prostate cancer survive in the era of individualized medicine?
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 24836154.
- Also identified by DOI 10.1016/j.eururo.2014.04.020.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The challenge for the next few years will be to individualize prostate cancer treatment and to determine whether or not a cancer will be lethal based on molecular characteristics at the time of diagnosis. In this view, the need for active treatment would represent a failure of any conservative approach.
Medical subject headings
- Adenocarcinoma
- Biomarkers, Tumor
- Bone Neoplasms
- Digital Rectal Examination
- Prostate
- Prostate-Specific Antigen
- Prostatic Neoplasms
- Soft Tissue Neoplasms
- Watchful Waiting